


PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3268.1005-001	APPLICATION NO. 10/729,427	
 INFORMATION DISCLOSURE CITATION IN AN APPLICATION April 30, 2004 (Use several sheets if necessary)		FIRST NAMED INVENTOR Kevin J. Tracey, <i>et al.</i>		FILING DATE December 5, 2003
		EXAMINER Not Yet Assigned	CONFIRMATION NO. 8405	GROUP 1614

U.S. PATENT DOCUMENTS				
EXAM- INER (INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
MG	AA	5,741,802	04-21-1998	Kem, <i>et al.</i>
	AB	5,902,814	05-11-1999	Gordon, <i>et al.</i>
	AC	5,977,144	11-02-1999	Meyer, <i>et al.</i>
	AD	5,998,429	12-07-1999	Macor, <i>et al.</i>
	AE	6,054,434	04-25-2000	Kropp, <i>et al.</i>
	AI	6,110,914	04-25-2000	Phillips, <i>et al.</i>
	AG	6,232,319 B1	05-15-2001	Marazano, <i>et al.</i>
	AH	US 2002/0040035 A1	04-04-2002	Myers, <i>et al.</i>
	AI	6,369,224 B1	04-09-2002	Phillips, <i>et al.</i>
	AJ	6,407,095 B1	06-18-2002	Lothead, <i>et al.</i>
	AK	6,432,975 B1	08-13-2002	Schmitt, <i>et al.</i>
	AA2	6,441,049 B2	08-27-2002	Reitz, <i>et al.</i>
	AB2	6,479,172 B2	11-12-2002	Hu, <i>et al.</i>
	AC2	6,479,510 B2	11-12-2002	Myers, <i>et al.</i>
	AD2	6,486,172 B2	11-26-2002	Myers, <i>et al.</i>
	AE2	6,492,386 B2	12-10-2002	Myers, <i>et al.</i>
	AF2	6,500,840 B2	12-31-2002	Myers, <i>et al.</i>
	AG2	6,538,003 B1	03-25-2003	Galli, <i>et al.</i>
	AH2	6,562,816 B2	05-13-2003	Wishka, <i>et al.</i>
	AI2	6,569,865 B2	05-27-2003	Eifion
	AJ2	US 2003/0105089 A1	06-05-2003	Wishka, <i>et al.</i>
	AK2	US 2003/0119837 A1	06-26-2003	O'Neill, <i>et al.</i>
	AA3	US 2003/0130305 A1	07-10-2003	Walker, <i>et al.</i>
	AB3	6,599,916 B2	07-29-2003	Myers, <i>et al.</i>
✓	AC3	US 2003/0149065 A1	08-07-2003	Loch III, <i>et al.</i>
MG	AD3	US 2003/0153595 A1	08-14-2003	Walker, <i>et al.</i>

EXAMINER /Michel Graffeo/	DATE CONSIDERED 02/12/2007
------------------------------	-------------------------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  April 30, 2004  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3268.1005-001	APPLICATION NO. 10/729,427	
	FIRST NAMED INVENTOR Kevin J. Tracey, <i>et al.</i>		FILING DATE December 5, 2003
	EXAMINER Not Yet Assigned	CONFIRMATION NO. 8405	GROUP 1614

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
MG	AE3	US 2003/0176416 A1	09-18-2003	Peters, <i>et al.</i>
↓	AF3	US 2003/0176702 A1	09-18-2003	Walker, <i>et al.</i>
↓	AG3	6,635,645 B1	10-21-2003	Lohead, <i>et al.</i>
↓	AH3	6,552,012	04-22-2003	Peters, <i>et al.</i>
↓	AI3	6,492,385	12-10-2002	Myers, <i>et al.</i>
MG	AJ3	US 2002/0086871 A1	07-04-2002	O'Neill, <i>et al.</i>

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
MG	AL	WO 01/85727 A1	11-15-2001	Novartis AG	
↓	AM	WO 02/44176 A1	06-06-2002	Neurosearch A/S	
↓	AN	WO 02/057275 A1	07-25-2002	University of Kentucky Research Foundation	
↓	AO	WO 03/032897 A2	04-25-2003	Astrazeneca AB	
↓	AP	WO 03/078431 A1	09-25-2003	Joachim Luithle, <i>et al.</i>	X
MG	AQ	JP 2002-030084 (Patent Abstract)	01-29-2002	Mitsubishi Pharma Corp.	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
MG	AR	Wang, <i>et al.</i> , "Nicotinic acetylcholine receptor $\alpha 7$ subunit is an essential regulator of inflammation," <i>Nature</i> , pp. 1-4 (2002).
↓	AS	Borovikova, <i>et al.</i> , "Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin," <i>Nature</i> , 405: 458-462 (2000).
↓	AT	Tracey, Kevin J., <i>et al.</i> , "Mind over immunity," <i>FASEB J.</i> , 15(9): 1575-1576 (2001).
↓	AU	Meyer, Edwin M., <i>et al.</i> , "3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat $\alpha 7$ receptors and improves memory-related behaviors in a mecamylamine-sensitive manner," <i>Brain Res.</i> , 768(1-2): 49-56 (1997).

EXAMINER /Michel Graffeo/	DATE CONSIDERED 02/12/2007
------------------------------	-------------------------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  April 30, 2004  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3268.1005-001		APPLICATION NO. 10/729,427	
	FIRST NAMED INVENTOR Kevin J. Tracey, <i>et al.</i>		FILING DATE December 5, 2003	
	EXAMINER Not Yet Assigned		CONFIRMATION NO. 8405	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
MG	AV	Alkondon, M., <i>et al.</i> , "Choline is a Selective Agonist of $\alpha 7$ Nicotinic Acetylcholine Receptors in the Rat Brain Neurons," <i>Eur. J. Neurosci.</i> , 9(12): 2734-2742 (1997).
	AW	Levin, E.D., <i>et al.</i> , "AR-R17779, an $\alpha 7$ nicotinic agonist, improves learning and memory in rats," <i>Behav. Pharmacol.</i> , 10(6-7): 675-680 (1999).
	AX	Kem, William R. "The brain $\alpha 7$ nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBBA (GTS-21)," <i>Behav. Brain Res.</i> , 113: 169-181 (2000).
	AY	Broad, Lisa M., <i>et al.</i> , "PSAB-OFP, a selective $\alpha 7$ nicotinic receptor agonist, is also a potent agonist of the 5-HT <sub>3</sub> receptor," <i>Eur. J. Pharmacol.</i> , 452(2): 137-144 (2002).
	AZ	Francis, Michael M., <i>et al.</i> , "Specific Activation of the $\alpha 7$ Nicotinic Acetylcholine Receptor by a Quaternary Analog of Cocaine," <i>Mol. Pharmacol.</i> , 60(1): 71-79 (2001).
MG	AR2	Mullen, George, <i>et al.</i> , "(-)-Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one], a Conformationally Restricted Analogue of Acetylcholine, Is a Highly Selective Full Agonist at the $\alpha 7$ Nicotinic Acetylcholine Receptor," <i>J. Med. Chem.</i> , 43(22): 4045-4050 (2000).

EXAMINER /Michel Graffeo/	DATE CONSIDERED 02/12/2007
------------------------------	-------------------------------